Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Spain set to limit retail price of COVID-19 antigen tests

Published 01/10/2022, 08:38 AM
Updated 01/10/2022, 02:45 PM
© Reuters. FILE PHOTO: People queue to get tested for the coronavirus disease (COVID-19) after the Christmas holiday break, amid the COVID-19 pandemic, at Doce de Octubre Hospital in Madrid, Spain December 27, 2021. REUTERS/Javier Barbancho
PFE
-

MADRID (Reuters) -Spain's government is working on rules to limit the retail price of antigen tests for COVID-19, Prime Minister Pedro Sanchez said on Monday, after shortages were reported in many pharmacies across the country last month.

Price rises during the surge in Omicron cases and the scarcity of tests in pharmacies have raised protests from opposition politicians and consumer groups, many of whom are calling for tests to be sold in supermarkets.

"The debate we had before and during the Christmas season was the supply of tests; there was a bottleneck," Sanchez said in an interview with Cadena SER radio station. "Now, we will get into the control of the tests' prices."

Sanchez said it might be time to use different parameters to track the pandemic as COVID-19 becomes less deadly, confirming a report that the authorities were considering monitoring it in a similar way to how they follow influenza, without recording every case or testing all symptomatic people.

Spain's COVID-19 infection rate as measured over the past 14 days hit a new record of 2,989 cases per 100,000 people on Monday, a more than tenfold increase since the start of December.

The COVID-19 intensive care occupancy rate in hospitals increased slightly to 23.6%, up from 8% a month ago but still about half the peak of 43% recorded a year ago.

A liberalisation of the market for antigen tests would be more efficient than a cap on prices, centre-right opposition leader Ines Arrimadas said on Monday.

"Not far from here, in Portugal, people can go and buy tests in their local super(market)," she told reporters.

Antigen tests sell for about 3 euros ($3.40) in neighbouring Portugal while they cost about 10 euros in Spain, where they are only available in pharmacies, Arrimadas said.

Spain will purchase 344,000 doses of Pfizer (NYSE:PFE)'s COVID-19 antiviral pill in January, Sanchez also said on Monday.

© Reuters. FILE PHOTO: People queue to receive free lateral flow coronavirus disease (COVID-19) tests at a pharmacy, as the regional authorities re-stocked the supplies after the Christmas in Madrid, Spain December 28, 2021. REUTERS/Javier Barbancho

The pill, Paxlovid, is for adults who have mild to moderate infection and are at high risk of their illness worsening. It is most effective when taken during the early stages of COVID-19, before any eventual hospitalisation.

($1 = 0.8834 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.